On April 25th, Southern Finance and Economics reported that the European Commission has approved the use of BeiGene Terezumab for first-line and second-line treatment of three indications for non-small cell lung cancer (NSCLC). This approval is the second approval obtained for rituximab in the European Union. Its indications for esophageal cancer have been approved in the EU in September 2023 and approved for market by the Food and Drug Administration (FDA) in March 2024. Tirelizumab is the first domestic product to go global in the PD - (L) 1 field, and it is also another self-developed core product of BeiGene after its BTK inhibitor Zebutinib. In addition to being approved for different indications in the EU region, it has also been approved in the UK, the US, South Korea, and Switzerland. (21st Century Business Herald)